Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 119

Results For "power"

1303 News Found

Takeda to acquire Adaptate Biotherapeutics
Biotech | January 11, 2022

Takeda to acquire Adaptate Biotherapeutics

Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Bayer and Mammoth Biosciences to collaborate on gene editing technology
Biotech | January 10, 2022

Bayer and Mammoth Biosciences to collaborate on gene editing technology

Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones


Jubiant Therapeutics gets USFDA clearance for JBI-802 to treat solid tumours
Biotech | January 07, 2022

Jubiant Therapeutics gets USFDA clearance for JBI-802 to treat solid tumours

JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6


NATHEALTH Home Care Forum launches white paper on healthcare delivery
Healthcare | January 06, 2022

NATHEALTH Home Care Forum launches white paper on healthcare delivery

10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies


Kyverna Therapeutics announces licence agreement with NIH
Biotech | January 04, 2022

Kyverna Therapeutics announces licence agreement with NIH

This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel


Snapdeal to promote Ayushman Bharat Digital Mission’s Heath ID
Public Health | January 03, 2022

Snapdeal to promote Ayushman Bharat Digital Mission’s Heath ID

The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records


VivaLyf Innovations to launch EzLyf, India's first non-invasive glucometer
Startup | December 30, 2021

VivaLyf Innovations to launch EzLyf, India's first non-invasive glucometer

The glucometer connects to one’s smartphone and provides actionable diagnostic information


Study demonstrates Covaxin safe for kids in the age 2-18 years
News | December 30, 2021

Study demonstrates Covaxin safe for kids in the age 2-18 years

Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults


Cipla receives EUA for Cipmolnu
Drug Approval | December 28, 2021

Cipla receives EUA for Cipmolnu

The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use